Table 1D.

Studies included in review.

Studyvan Dijken, et al3
Publish yr2011
Study designObservational
SexFFFFFFFFFFMMM
Age at IBD onset, yrs813.112.733.526.417.611.78.415.310.38.312.510
Underlying diseasePoly JIAOligo JIAOligo JIAPoly JIASystemic JIAERA JIAOligo JIAERA JIASystemic JIAPoly JIAOligo JIAOligo JIAPoly JIA
Age at rheumatic disease onset, yrs1.61.93.316.814.186.73.35.85.8111.47.08
Duration of ETN treatment, yrs5.91.34.81.50.70.81.31.13.62.50.30.11.3
Time from disease diagnosis to ETN start, yrs0.69.94.816.61216.810.44.29.33.38.112.42.8
Time from ETN to IBD, yrs5.81.34.51.40.30.81.3132.30.100.4
CD/UCUCCDIDCDCDCDCDUCCDCDCDCDUC
BiopsyYYYYYYYYYYYYY
Concomitant treatmentNoneNoneNonsPSL, CSAPSL, CSAETN cont.ADANoneNoneNoneMTX, PSLNSAID, omeprazole, PSLNSAID
Decrease in IBD symptomsIBD improvedIBD improvedIBD improvedIBD improvedIBD improvedNSNSIBD improvedIBD improvedNSIBD persistedIBD improvedIBD improved
IBD treatment afterIFX, ADAMSZ, IFX, ADANSADAIFX, SSZETN, MTX, PSL, SSZADAIFX, BUD, MSZMSZPSL, ADAPSLIFX, BUD, MSZIFX
IBD progression: penetrating, stricturing, inflammatoryNSNSInflammatoryNSNSNSNSInflammatoryNSInflammatoryInflammatoryNSInflammatory
  • IBD: inflammatory bowel disease; ETN: etanercept; CD: Crohn disease; UC: ulcerative colitis; NS: not specified; poly: polyarticular; JIA: juvenile idiopathic arthritis; oligo: oligoarticular; ERA: enthesitis-related arthritis; ID: undifferentiated IBD; PSL: prednisone; CSA: cyclosporine; ETN cont.: ETN continuous; ADA: adalimumab; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drugs; IFX: infliximab; MSZ: mesalazine; SSZ: sulfasalazine; BUD: budesonide.